109 related articles for article (PubMed ID: 33608886)
1. Epigenetic modulators combination with chemotherapy in breast cancer cells.
Ari F; Napieralski R; Akgun O; Magdolen V; Ulukaya E
Cell Biochem Funct; 2021 Jun; 39(4):571-583. PubMed ID: 33608886
[TBL] [Abstract][Full Text] [Related]
2. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
3. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
4. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.
Vijayaraghavalu S; Labhasetwar V
Drug Deliv Transl Res; 2018 Oct; 8(5):1289-1299. PubMed ID: 29947019
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modifiers 5-aza-2'-deoxycytidine and valproic acid differentially change viability, DNA damage and gene expression in metastatic and non-metastatic colon cancer cell lines.
Ghecham A; Senator A; Pawlowska E; Bouafia W; Błasiak J
Acta Biochim Pol; 2019 Jul; 66(3):355-360. PubMed ID: 31284710
[TBL] [Abstract][Full Text] [Related]
6. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
7. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.
Mongan NP; Gudas LJ
Mol Cancer Ther; 2005 Mar; 4(3):477-86. PubMed ID: 15767557
[TBL] [Abstract][Full Text] [Related]
9. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
10. Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance.
Dahn ML; Cruickshank BM; Jackson AJ; Dean C; Holloway RW; Hall SR; Coyle KM; Maillet H; Waisman DM; Goralski KB; Giacomantonio CA; Weaver ICG; Marcato P
Mol Cancer Ther; 2020 May; 19(5):1110-1122. PubMed ID: 32156786
[TBL] [Abstract][Full Text] [Related]
11. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Guo Y; Pakneshan P; Gladu J; Slack A; Szyf M; Rabbani SA
J Biol Chem; 2002 Nov; 277(44):41571-9. PubMed ID: 12198113
[TBL] [Abstract][Full Text] [Related]
12. Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid in breast cancer cells in vitro.
Lirk P; Hollmann MW; Fleischer M; Weber NC; Fiegl H
Br J Anaesth; 2014 Jul; 113 Suppl 1():i32-8. PubMed ID: 24946779
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines.
Patties I; Kortmann RD; Glasow A
J Exp Clin Cancer Res; 2013 May; 32(1):27. PubMed ID: 23672687
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine, a novel adenosine analogue, reactivates DNA methylation-silenced tumour suppressor genes and inhibits cell growth in breast cancer cells.
Lubecka-Pietruszewska K; Kaufman-Szymczyk A; Stefanska B; Cebula-Obrzut B; Smolewski P; Fabianowska-Majewska K
Eur J Pharmacol; 2014 Jan; 723():276-87. PubMed ID: 24296317
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells.
Zeng L; Jarrett C; Brown K; Gillespie KM; Holly JM; Perks CM
Exp Cell Res; 2013 Aug; 319(14):2282-95. PubMed ID: 23810988
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
17. Selenium Nanoparticles Induce the Chemo-Sensitivity of Fluorouracil Nanoparticles in Breast and Colon Cancer Cells.
Abd-Rabou AA; Shalby AB; Ahmed HH
Biol Trace Elem Res; 2019 Jan; 187(1):80-91. PubMed ID: 29748931
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
19. Network assessment of demethylation treatment in melanoma: Differential transcriptome-methylome and antigen profile signatures.
Jiang Z; Cinti C; Taranta M; Mattioli E; Schena E; Singh S; Khurana R; Lattanzi G; Tsinoremas NF; Capobianco E
PLoS One; 2018; 13(11):e0206686. PubMed ID: 30485296
[TBL] [Abstract][Full Text] [Related]
20. Long-term genistein treatment of MCF-7 cells decreases acetylated histone 3 expression and alters growth responses to mitogens and histone deacetylase inhibitors.
Jawaid K; Crane SR; Nowers JL; Lacey M; Whitehead SA
J Steroid Biochem Mol Biol; 2010 Jun; 120(4-5):164-71. PubMed ID: 20399854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
